Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Shares Issued (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Shares Issued for 15 consecutive years, with $14.8 million as the latest value for Q2 2025.

  • On a quarterly basis, Shares Issued rose 338.92% to $14.8 million in Q2 2025 year-over-year; TTM through Jun 2025 was $18.2 million, a 146.8% increase, with the full-year FY2025 number at $14.8 million, up 328.04% from a year prior.
  • Shares Issued was $14.8 million for Q2 2025 at Aytu Biopharma, up from $3.4 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $14.8 million in Q2 2025 to a low of -$1.0 million in Q2 2022.
  • A 5-year average of $4.9 million and a median of $3.4 million in 2024 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 3292.83% in 2022; the steepest drop was 112.74% in 2022.
  • Aytu Biopharma's Shares Issued stood at $4.5 million in 2021, then crashed by 74.39% to $1.2 million in 2022, then surged by 121.52% to $2.6 million in 2023, then surged by 31.92% to $3.4 million in 2024, then skyrocketed by 338.92% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Shares Issued are $14.8 million (Q2 2025), $3.4 million (Q2 2024), and $2.6 million (Q2 2023).